Revenue Recognition (Tables)

12 Months Ended

Dec. 31, 2024

Revenue Recognition

Schedule of disaggregation of revenues by payer types

	Year Ended December 31,
	2024		2023		2022
	(in thousands)
Insurance carriers	$	1,571,817	$	954,155	$	690,754
Laboratory partners		97,210		98,891		94,910
Patients		27,884		29,525		34,558
Total revenues	$	1,696,911	$	1,082,571	$	820,222

Schedule of total revenue by geographic area

	Year ended December 31,
	2024		2023		2022
	(in thousands)
United States	$	1,657,745	$	1,047,636	$	785,849
Americas, excluding U.S.		6,620		4,908		3,705
Europe, Middle East, India, Africa		23,884		22,811		16,640
Asia Pacific and Other		8,662		7,216		14,028
Total	$	1,696,911	$	1,082,571	$	820,222

Schedule of beginning and ending balances of accounts receivable and deferred revenues

	Balance at		Balance at
	December 31,		December 31,
	2024		2023
	(in thousands)
Assets:
Accounts receivable, net	$	314,165	$	278,289
Liabilities:
Deferred revenue, current portion	$	19,754	$	16,612
Deferred revenue, long-term portion (1)		16,838		19,128
Total deferred revenues	$	36,592	$	35,740

Schedule of changes in the balance of deferred revenues

	Balance at		Balance at
	December 31,		December 31,
	2024		2023
	(in thousands)
Beginning balance	$	35,740	$	30,778
Increase in deferred revenues		35,440		35,573
Reclasses from deferred revenues to other short-term liabilities		—		(522)
Revenue recognized during the period that was included in deferred revenues at the beginning of the period		(13,693)		(10,564)
Revenue recognized from performance obligations satisfied within the same period		(20,895)		(19,525)
Ending balance	$	36,592	$	35,740